Timing of Atrial Fibrillation Diagnosis Does Not Alter Early Anticoagulation Benefits in Stroke Patients: Insights from the OPTIMAS Trial
Posted inCardiology Neurology news

Timing of Atrial Fibrillation Diagnosis Does Not Alter Early Anticoagulation Benefits in Stroke Patients: Insights from the OPTIMAS Trial

Subgroup analysis of the OPTIMAS trial reveals that neither the timing of atrial fibrillation diagnosis nor AF subtype modifies the treatment effect of early versus delayed direct oral anticoagulant initiation in acute ischemic stroke. Persistent AF, however, confers approximately double the risk of adverse outcomes compared with paroxysmal AF.
Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis
Posted inCardiology Hematology-Oncology news

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer alternative for high-risk geriatric populations.
GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
Posted inCardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.
Ultra-Early ILR Implantation Post-Cryptogenic Stroke Dramatically Improves Silent AF Detection: Insights from the CRIPTOFAST Trial
Posted inCardiology Neurology news

Ultra-Early ILR Implantation Post-Cryptogenic Stroke Dramatically Improves Silent AF Detection: Insights from the CRIPTOFAST Trial

The CRIPTOFAST trial demonstrates that ultra-early implantation of internal loop recorders significantly increases silent atrial fibrillation detection in cryptogenic stroke patients, particularly those with subtle left atrial anomalies, offering a targeted approach to secondary stroke prevention.
Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial
Posted inCardiology Neurology news

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial

The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the trial was halted early for futility, highlighting the complexity of AF-related neurocognitive impairment.
Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study
Posted inCardiology Neurology news

Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study

A secondary analysis of the LOOP study demonstrates that continuous ECG screening with implantable loop recorders significantly reduces stroke and systemic embolism in individuals with high genetic risk for atrial fibrillation, while potentially increasing bleeding risk in lower-risk cohorts.
Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes
Posted inCardiology news

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

This study identifies key plasma biomarkers—including NT-proBNP, FGF-23, and GDF-15—that predict heart failure hospitalization in patients with atrial fibrillation. Findings also reveal distinct pathophysiological pathways for HFrEF and HFpEF, highlighting the roles of inflammation and adipose metabolism.